[Three-Dimensional Ultrasonic Gait Analysis in Schizophrenic Patients]

Area of Science:

• Neuroscience
• Movement Science
• Psychiatry

Background:

• Schizophrenia and its treatments can significantly impact motor function.
• Locomotion and gait are crucial aspects of daily functioning affected by neurological and psychiatric conditions.
• Neuroleptic medications are standard treatments for schizophrenia, but their effects on gait require objective assessment.

Purpose of the Study:

• To investigate the influence of neuroleptic treatment on human gait parameters in schizophrenia patients.
• To objectively measure changes in spatio-temporal and kinematic gait parameters using ultrasonic gait analysis.
• To compare the effects of conventional neuroleptics versus atypical neuroleptic olanzapine on gait.

Main Methods:

• Utilized a repeated measures design with ultrasonic topometric gait analysis.
• Assessed spatio-temporal gait parameters in three groups: untreated schizophrenic patients, patients on conventional neuroleptics, and patients switched to olanzapine.
• Established high test-retest reliability of the gait analysis system in a control sample.

Main Results:

• Patients switching from conventional neuroleptics to olanzapine demonstrated significant increases in gait velocity and step length (p <= 0.01).
• Cadence remained stable after switching to olanzapine.
• No significant differences in gait parameters were detected between the untreated state and olanzapine treatment.

Conclusions:

• Conventional neuroleptic treatment demonstrably affects bipedal gait in schizophrenia patients.
• Three-dimensional ultrasonic gait analysis provides an objective method to quantify neuroleptic-induced gait impairments.
• Switching to olanzapine may improve gait disturbances associated with conventional neuroleptic use.